Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.42 |
| ▸ | IL1B | P01584 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387949 | 1.00 | OXTR (0.48) | OXTRHRH3IL1BP2RX7MEN1 | |
| SCHEMBL3388801 | 1.00 | OXTR (0.48) | OXTRHRH3IL1BP2RX7MEN1 | |
| SCHEMBL3390200 | 0.89 | HRH3 (0.42) | OXTRHRH3CNR2CHRNA7 | |
| SCHEMBL3387650 | 0.88 | OXTR (0.50) | OXTRHRH3MEN1KMT2A | |
| SCHEMBL3387054 | 0.88 | OXTR (0.50) | OXTRHRH3MEN1KMT2A | |
| SCHEMBL3387045 | 0.88 | OXTR (0.50) | OXTRHRH3MEN1KMT2A | |
| SCHEMBL3390065 | 0.86 | HRH3 (0.43) | OXTRHRH3MEN1KMT2ACNR2 | |
| SCHEMBL3390210 | 0.86 | HRH3 (0.43) | OXTRHRH3MEN1KMT2ACNR2 | |
| SCHEMBL3390207 | 0.86 | HRH3 (0.43) | OXTRHRH3MEN1KMT2ACNR2 | |
| SCHEMBL3383957 | 0.85 | HRH3 (0.47) | HRH3MEN1KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029534-B1 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-12-22 | — | — | EP | disclosed |
| EP-2029534-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| US-7432255-B2 | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2007131907-A2 | 1H-INDOL-5-YL-PIPERAZIN-1-YL-METHANONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HOFFMANN-LA ROCHE INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270423-A1 | IH-indol-5-YL-piperazin-1-YL-methanone derivatives | HRH4, HRH2, HRH3 | OXTR 368/4885HRH3 3/4885IL1B 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.